Who are Simvastatin/Ezetimibe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atorvastatin, Ezetimibe, atorvastatin plus ezetimibe, statins, ezetimibe, Experimental: Rosuvastatin/Ezetimibe 10, statin + ezetimibe + Nutraceuticals, statin + ezetimibe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/simvastatin-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Simvastatin/Ezetimibe — Competitive Intelligence Brief

Simvastatin/Ezetimibe (Simvastatin/Ezetimibe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin/Ezetimibe combination. Area: Cardiovascular.

marketed Statin/Ezetimibe combination HMG-CoA reductase; NPC1L1 transporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Simvastatin/Ezetimibe (Simvastatin/Ezetimibe) — dr.Frank L.J. Visseren. Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Simvastatin/Ezetimibe TARGET	Simvastatin/Ezetimibe	dr.Frank L.J. Visseren	marketed	Statin/Ezetimibe combination	HMG-CoA reductase; NPC1L1 transporter
Atorvastatin, Ezetimibe	Atorvastatin, Ezetimibe	Abant Izzet Baysal University	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
atorvastatin plus ezetimibe	atorvastatin plus ezetimibe	Shanghai Jiao Tong University School of Medicine	marketed	Statin plus cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
statins, ezetimibe	statins, ezetimibe	Korea University Anam Hospital	marketed	HMG-CoA reductase inhibitor and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
Experimental: Rosuvastatin/Ezetimibe 10	Experimental: Rosuvastatin/Ezetimibe 10	Keun-Sik Hong	marketed	Statin/ezetimibe combination	HMG-CoA reductase; NPC1L1 transporter
statin + ezetimibe + Nutraceuticals	statin + ezetimibe + Nutraceuticals	University of Roma La Sapienza	marketed	Lipid-lowering combination therapy	HMG-CoA reductase; NPC1L1 transporter; multiple nutraceutical targets
statin + ezetimibe	statin + ezetimibe	University of Roma La Sapienza	marketed	Lipid-lowering agent combination (statin + cholesterol absorption inhibitor)	HMG-CoA reductase; NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin/Ezetimibe combination class)

dr.Frank L.J. Visseren · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simvastatin/Ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/simvastatin-ezetimibe. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab